T2 Bio Sets Price Range for Planned IPO, Eyes $65.9M in Net Proceeds | GenomeWeb

NEW YORK (GenomeWeb) – T2 Biosystems today set a price range of between $15 and $17 per share on its planned initial public offering, with anticipated net proceeds of up to $65.9 million.

In an amended preliminary prospectus filed with the US Securities and Exchange Commission, the molecular diagnostics firm said it plans to offer 4 million shares of its common stock. At the $16 midpoint price, the offering would bring in net proceeds of $57 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: role for epigenetic in neuronal excitability, and more.

The new Office of Research Integrity director is grappling with complaints from her staff, according to ScienceInsider.

Italian researchers link SNPs in the PDSS2 gene to coffee consumption in a new paper.

A gene-editing ban has been interpreted to include mitochondrial transfer, Technology Review reports.